Clinical trial WO29636
WO29636 A Phase III, Open-Label, Multicenter, Randomized Study Of Atezolizumab (Anti?Pd-L1 Antibody) Versus Observation As Adjuvant Therapy In Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection
| Cancers | |
|---|---|
| Organ | Ureters - bladder - urethra |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Roche |
| EudraCT Identifier | 2014-005603-25 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02450331 |
| Inclusion criteria | Absence of metastasis |
| Last update |